Rachel Brough

9.5k citations

39 papers · 3.1k indexed · 1 hit paper · h-index 21

Impact in

Oncology top 1%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Molecular Biology top 5%
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Cancer therapeutics and mechanisms

Papers in

Oncology 24
- PARP inhibition in cancer therapy 14
- Cancer-related Molecular Pathways 6
Molecular Biology 29
- DNA Repair Mechanisms 16
- CRISPR and Genetic Engineering 15
- Chromatin Remodeling and Cancer 4
- RNA Interference and Gene Delivery 3

Co-authors: Christopher J. Lord Alan Ashworth Rachael Natrajan Jorge S. Reis‐Filho Radost Vatcheva Douglas A. Levine Stacey L. Edwards Jeff Boyd
Journals: Oncogene (4 papers)Cancer Research (3 papers)Molecular Cancer Therapeutics (2 papers)British Journal of Cancer (2 papers)EMBO Molecular Medicine (2 papers)
Partner nations: United Kingdom United States Italy

In The Last Decade

Rachel Brough

38 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Resistance to therapy caused by intragenic deletion in BRCA2 2008 · 754 citations

Peers

Countries citing papers authored by Rachel Brough

Since Specialization

Citations

This map shows the geographic impact of Rachel Brough's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Brough with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Brough more than expected).

Fields of papers citing papers by Rachel Brough

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Brough. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Brough. The network helps show where Rachel Brough may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rachel Brough, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rachel Brough Line = papers co-authored together Rachel Brough links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The transcriptomic architecture of common cancers reflects synthetic lethal interactions Nature Genetics ·Syed Haider, Rachel Brough, Aalizad Ismail, Jacopo Iacovacci, Aditi Gulati, Andrew J. Wicks, John Alexander, Stephen J. Pettitt, Andrew Tutt, Christopher J. Lord	2025	2
2	Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer British Journal of Cancer ·John Alexander, Koen Schipper, Sarah H. Nash, Rachel Brough, Harriet Kemp, Jacopo Iacovacci, Clare M. Isacke, Rachael Natrajan, Elinor J. Sawyer, Christopher J. Lord, Syed Haider	2024	2
3	A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant Oncogene ·Stephen J. Pettitt, Nan Shao, Diana Zatreanu, Jessica Frankum, Ilirjana Bajrami, Rachel Brough, Dragomir B. Krastev, Theodoros I. Roumeliotis, Jyoti S. Choudhary, Sonja Lorenz, Alistair G. Rust, Johann S. de Bono, Timothy A. Yap, Andrew Tutt, Christopher J. Lord	2023	3
4	Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance Oncogene ·Ruimário Inácio Coelho, 維康玉村, Daniel Weekes, Helen N. Pemberton, Kathryn Davidson, Gonzalo Torga, Jessica Frankum, Ana M. Mendes‐Pereira, 琢也柏崎, Riccardo Ferro, Rachel Brough, Stephen J. Pettitt, Christopher J. Lord, Anita Grigoriadis, Andrew Tutt	2022	9
5	3P Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma Annals of Oncology ·泰成萱嶋, Hildur Kristjánsdóttir, Diana Zatreanu, Rachel Brough, Feifei Song, Asha Konde, Dragomir B. Krastev, John Alexander, Rachael Natrajan, Stephen J. Pettitt, Susana Banerjee, Christopher J. Lord	2022	1
6	Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer Oncogene ·Rachel Brough, Aditi Gulati, Syed Haider, Rahul Kumar, James Campbell, Erik S. Knudsen, Stephen J. Pettitt, Colm J. Ryan, Christopher J. Lord	2018	22
7	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells Cell Reports ·Marco Barazas, Stefano Annunziato, Stephen J. Pettitt, Inge de Krijger, Fahmi Riskian, Stefan J. Roobol, Catrin Lutz, Jessica Frankum, Fei Song, Rachel Brough, Bastiaan Evers, Ewa Gogola, Jinhyuk Bhin, Marieke van de Ven, Dik C. van Gent, Jacqueline J.L. Jacobs, J. Ross Chapman, Christopher J. Lord, Jos Jonkers, Sven Rottenberg	2018	102
8	Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers Molecular Cancer Therapeutics ·Amy Dréan, Chris T. Williamson, Rachel Brough, Inger Brandsma, Malini Menon, Asha Konde, Isaac García-Murillas, Helen N. Pemberton, Jessica Frankum, Rumana Rafiq, Nicholas Badham, James Campbell, Aditi Gulati, Nicholas C. Turner, Stephen J. Pettitt, Alan Ashworth, Christopher J. Lord	2017	58
9	ATR Is a Therapeutic Target in Synovial Sarcoma Cancer Research ·Samuel E. Jones, Emmy D.G. Fleuren, Jessica Frankum, Asha Konde, Chris T. Williamson, Dragomir B. Krastev, Helen N. Pemberton, James Campbell, Aditi Gulati, Richard Elliott, Malini Menon, Joanna Selfe, Rachel Brough, Stephen J. Pettitt, Wojciech Niedźwiedź, Winette T.A. van der Graaf, Janet Shipley, Alan Ashworth, Christopher J. Lord	2017	47
10	Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells Scientific Data ·Stephen J. Pettitt, Dragomir B. Krastev, Helen N. Pemberton, Henrique Perazzi de [UNESP] Aquino, Jessica Frankum, Farah Rehman, Rachel Brough, Feifei Song, Ilirjana Bajrami, Rumana Rafiq, Fredrik Wållberg, Iwanka Kozarewa, Kerry Fenwick, محمد مهدي سيف آل سلطان القحطاني, Amanda Swain, Aditi Gulati, James Campbell, Alan Ashworth, Christopher J. Lord	2017	13
11	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours PLoS ONE ·Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna L. Riffell, Alberto Bardelli, C Torrance, Christopher J. Lord, Alan Ashworth	2016	58
12	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A Nature Communications ·Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeffrey C. Francis, Jeronimo Delgado, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord	2016	270
13	Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways Molecular Cancer Therapeutics ·Marieke Aarts, Ilirjana Bajrami, María Teresa Herrera-Abreu, Richard Elliott, Rachel Brough, Alan Ashworth, Christopher J. Lord, Nicholas C. Turner	2015	48
14	Druggable Genetic Dependencies for Molecularly Defined Subgroups of Oesophageal Cancer Identified From High-Throughput Functional Profiling Annals of Oncology ·Irene Chong, David Cunningham, James Campbell, Ilirjana Bajrami, Rachel Brough, Jessica Frankum, Krzysztof Lubiński, Alan Ashworth	2014	0
15	Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity Cancer Research ·Ilirjana Bajrami, Jessica Frankum, Asha Konde, Rowan Miller, Farah Rehman, Rachel Brough, James Campbell, David Sims, Rumana Rafiq, Sean Hooper, Lina Chen, Iwanka Kozarewa, Ioannis Assiotis, Kerry Fenwick, Rachael Natrajan, Christopher J. Lord, Alan Ashworth	2013	279
16	Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells Human Mutation ·陈良俊, Andrew C.G. Porter, Dennis Strand, Rachel Brough, Darja Karpova, Reinhold Kerb, Leszek Wojnowski, Matthias Schwab, Thomas Lang	2012	18
17	APRIN is a cell cycle specific BRCA2‐interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer The EMBO Journal ·Rachel Brough, Ilirjana Bajrami, Radost Vatcheva, Rachael Natrajan, Jorge S. Reis‐Filho, Christopher J. Lord, Alan Ashworth	2012	58
18	Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Molecular Medicine ·Ana M. Mendes‐Pereira, Sarah A. Martin, Rachel Brough, Afshan McCarthy, The Nu Tran, Jung‐Sik Kim, Todd Waldman, Christopher J. Lord, Alan Ashworth	2009	486
19	Resistance to therapy caused by intragenic deletion in BRCA2 Nature ·Stacey L. Edwards, Rachel Brough, Christopher J. Lord, Rachael Natrajan, Radost Vatcheva, Douglas A. Levine, Jeff Boyd, Jorge S. Reis‐Filho, Alan Ashworth Hit paper breakdown →	2008	754
20	Functional analysis of Drosophila melanogaster BRCA2 in DNA repair DNA repair ·Rachel Brough, Debbie Wei, T. Sinmyozu, Christopher J. Lord, Yikang S. Rong, Alan Ashworth	2007	24

About Rachel Brough

Rachel Brough is a scholar working on Oncology, Molecular Biology, Geriatrics and Gerontology, Genetics and Genetics, having authored 39 papers that have together received 3.1k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (16 papers), CRISPR and Genetic Engineering (15 papers), PARP inhibition in cancer therapy (14 papers), BRCA gene mutations in cancer (6 papers), Cancer-related Molecular Pathways (6 papers), Chromatin Remodeling and Cancer (4 papers), Advanced Breast Cancer Therapies (3 papers) and RNA Interference and Gene Delivery (3 papers). The work is most often cited by research in Oncology (2.1k citations), Molecular Biology (2.4k citations), Reproductive Medicine (288 citations), Cancer Research (448 citations) and Genetics (480 citations). Rachel Brough has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Christopher J. Lord, Alan Ashworth, Rachael Natrajan, Jorge S. Reis‐Filho, Radost Vatcheva, Douglas A. Levine, Stacey L. Edwards, Jeff Boyd, Jessica Frankum and Ilirjana Bajrami. Their work appears in journals such as Oncogene, Cancer Research, Molecular Cancer Therapeutics, British Journal of Cancer and EMBO Molecular Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact